Home > Academic Information

Recently Published Articles

Snoeck E, Chanu P, Lavielle M, Jacqmin P, Jonsson EN, Jorga K, Goggin T, Grippo J, Jumbe NL, Frey N.
A comprehensive hepatitis C viral kinetic model explaining cure.
Clin Pharmacol Ther. 2010 Advance publication.

Jacqmin P, McFadyen L, Wade JR.
Basic PK/PD principles of drug effects in circular/proliferating systems for disease modelling.
J Pharmacokinet Pharmacodyn. 2010;37:157-177.

Toublanc N, Sargentini-Maier ML, Lacroix B, Jacqmin P, Stockis A.
Retrospective population pharmacokinetic analysis of levetiracetam in
children and adolescents with epilepsy: dosing recommendations.
Clin Pharmacokinet. 2008;47(5):333-41.

Jacqmin P, McFadyen L, Wade JR.
A receptor theory-based semimechanistic PD model for the CCR5 noncompetitive
antagonist maraviroc.
Br J Clin Pharmacol. 2008;65 Suppl 1:95-106.

Rosario MC, Jacqmin P, Dorr P, James I, Jenkins TM, Abel S, van der Ryst E.
Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor
occupancy by maraviroc in healthy subjects and HIV-positive patients.
Br J Clin Pharmacol. 2008;65 Suppl 1:86-94.

Snoeck E, Hadziyannis SJ, Puoti C, Swain MG, Berg T, Marcellin P, Zarski J-P, Jorga K and Zeuzum S.
Predicting eficacy and safetyoutcomes in patients with hepatitis C virus genotype 1 and persistently 'normal'
alanine aminotransferase levels treated with peginterferon -2a (40KD) plus ribavirin.
Liver International. 2007;28 (1):61-71.

Snoeck E, Jacqmin P, Sargentini-Maier ML, Stockis A.
Modeling and simulation of intravenous levetiracetam pharmacokinetic
profiles in children to evaluate dose adaptation rules.
Epilepsy Res. 2007 Sep;76(2-3):140-7. Epub 2007 Sep 11.
Erratum in: Epilepsy Res. 2008 Feb;78(2-3):246.

Pigeolet E, Jacqmin P, Sargentini-Maier ML, Stockis A.
Population pharmacokinetics of levetiracetam in Japanese and Western adults.
Clin Pharmacokinet. 2007;46(6):503-12.

Maloney A, Karlsson MO, Simonsson US.
Optimal adaptive design in clinical drug development: a simulation example.
J Clin Pharmacol. 2007 Oct;47(10):1231-43.

Olsson-Gisleskog P, Jacqmin P, Perez-Ruixo JJ.
Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects.
Clinical Pharmacokinetics, 2007;46 (2):159-173.

Dartois C, Lemenuel-Diot A, Laveille C, Tranchand B, Tod M, Girard P.
Evaluation of uncertainty parameters estimated by different population PK software and methods.
J Pharmacokinet Pharmacodyn. 2007;34 (3):289-311.

Snoeck E, Stockis A.
Dose-response population analysis of levetiracetam add-on treatment in refractory epileptic patients with partial onset seizures.
Epilepsy Res. 2006;73(3):284-291.

Wade JR, Snoeck E, Duff F, Lamb M, Jorga K.
Pharmacokinetics of ribavirin in patients with hepatitis C virus.
Br J Clin Pharmacol. 2006;62(6):710-4.

Snoeck E, Wade JR, Duff F, Lamb M, Jorga K.
Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin.
Br J Clin Pharmacol. 2006;62(6):699-709.

Jacqmin P, Snoeck E, van Schaick EA, Gieschke R, Pillai P, Steimer JL, Girard P.
Modelling Response Time Profiles in the Absence of Drug Concentrations: Definition and Performance Evaluation of the K-PD Model.
J Pharmacokinet Pharmacodyn. 2006;34(1):57-85.

Brendel K, Comets E, Laffont C, Laveille C, Mentré F.
Metrics for External Model Evaluation with an Application to the Population Pharmacokinetics of Gliclazide
Pharmaceutical Research, 2006;23(9):2036-2049.

Wade JR, Edholm M, Salmonson T.
A guide for reporting the results of population pharmacokinetic analyses: a Swedish perspective.
AAPS J. 2005 Oct 5;7(2):45.

Rosario MC, Jacqmin P, Dorr P, van der Ryst E, Hitchcock C.
A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc.
Clin Pharmacol Ther. 2005 Nov;78(5):508-19.

Jacqmin P, Labouret N, Gueyffier F; Round Table No. 6, Giens XX.
Modelling and clinical trials in paediatrics.
Therapie. 2005 Jul-Aug;60(4):379-84, 385-90 (English and French).

Burman C-F, Hamrén B, Olsson P.
Modelling and simulation to improve decision-making in clinical development.
Pharm. Stat., 2005;4(1):47-58.